Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Dalya Guris"'
Autor:
Anitta Ahonen, Ying Zhang, Tomáš Marček, Jessie Lumley, David R. Johnson, Dalya Guris, Marissa B. Wilck
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
Vaccination against hepatitis B (HepB) provides long-term protection against infection. This is despite a reduction in HepB surface antibody (anti-HBs) concentrations over time to levels below the well-accepted correlate of protection of ≥10 mIU/mL
Externí odkaz:
https://doaj.org/article/b380cb3fa1434487b1bf988329caeca2
Autor:
Jonathan A. Robbins, Dereck Tait, Qinlei Huang, Sheri Dubey, Tami Crumley, Josee Cote, Julie Luk, Jeffrey R. Sachs, Kathryn Rutkowski, Harriet Park, Robert Schwab, William Joseph Howitt, Juan Carlos Rondon, Martha Hernandez-Illas, Terry O'Reilly, William Smith, Jakub Simon, Cathy Hardalo, Xuemei Zhao, Richard Wnek, Alethea Cope, Eseng Lai, Paula Annunziato, Dalya Guris, S. Aubrey Stoch
Publikováno v:
EBioMedicine, Vol 82, Iss , Pp 104138- (2022)
Summary: Background: Vaccines against COVID-19 are needed to overcome challenges associated with mitigating the global pandemic. We report the safety and immunogenicity of V590, a live recombinant vesicular stomatitis virus-based COVID-19 vaccine can
Externí odkaz:
https://doaj.org/article/a44da410c7ec4f96838eaf6361e76d18
Autor:
Farrel J Buchinsky, Nicole Ruszkay, William Valentino, Craig S Derkay, John E McClay, Robert W Bastian, Charles M Myer, Kevin W Lollar, Dalya Guris
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0230106 (2020)
BACKGROUND:Recurrent respiratory papillomatosis (RRP) is characterized by repeated formation of papillomas in the respiratory tract and is caused by human papillomavirus (HPV) types 6 and 11. Women with genital HPV infection are slow to develop weak
Externí odkaz:
https://doaj.org/article/741f465a441c4c7e933753e62961b212
Autor:
Mary Beth Dorr, Ciaran P. Kelly, Ian R. Poxton, Xuemei Zhao, Radha Railkar, Dalya Guris, Mark H. Wilcox, Judong Shen, Dale N. Gerding, Omar F Laterza
Publikováno v:
Clinical Infectious Diseases. 71:81-86
Background Endogenous antibodies (eAbs) against Clostridioides (Clostridium) difficile toxins may protect against recurrence of C. difficile infection (rCDI). This hypothesis was tested using placebo group data from MODIFY (Monoclonal Antibodies for
Autor:
Dalya Guris, Karen Eves, Mary Beth Dorr, Dale N. Gerding, Christine H. Lee, Misoo C. Ellison, Ciaran P. Kelly, Bruce R. Yacyshyn, Erik R. Dubberke, Dina Kao, Galia Rahav, Mary E. Hanson, Princy Kumar
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B indicated to prevent C. difficile infection (CDI) recurrence (rCDI) in adults at high risk for rCDI. This post hoc analysis of pooled monocolonal antibodies
Autor:
U Stoutenburgh, Dalya Guris, Yoshihiko Murata, Mandy Jin, Laurent Chesnel, Kajal B. Larson, P Daley, Sahil Khanna, Thomas J. Louie, J E Lutz, Adedayo Adedoyin
Publikováno v:
Journal of Antimicrobial Chemotherapy. 72:3462-3470
Background The available treatment options for Clostridium difficile infection (CDI) are limited by high recurrence rates. Surotomycin was a novel bactericidal cyclic lipopeptide in development to treat CDI that demonstrated non-inferiority to vancom
Autor:
Karen Eves, Mark H. Wilcox, Kerrie Davies, Claire Berry, Misoo C. Ellison, Galia Rahav, Erik R. Dubberke, Lori Gabryelski, Mary Beth Dorr, Dalya Guris
Publikováno v:
Open Forum Infectious Diseases
Background The optimum diagnostic test method for Clostridioides difficile infection (CDI) remains controversial due to variation in accuracy in identifying true CDI. This post hoc analysis examined the impact of CDI diagnostic testing methodology on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de8e4c6e980a727b06407e7eb4af89e3
Autor:
Zhen Zeng, Ian R. Poxton, Hailong Zhao, Mary Beth Dorr, Mark H. Wilcox, Peter M. Shaw, Junhua Li, Dalya Guris, Judong Shen
Publikováno v:
Anaerobe. 61:102137
Bezlotoxumab has been shown to prevent Clostridium difficile infection recurrence (rCDI) in high-risk patients.We used whole genome sequencing to estimate the impact of bezlotoxumab on same-strain relapse or new-strain reinfection in MODIFY I/II tria
Autor:
Thomas Birch, Dalya Guris, Erin Jensen, Mary Beth Dorr, Lori Gabryelski, Yoav Golan, Giuliano Rizzardini
Publikováno v:
The Journal of antimicrobial chemotherapy. 73(9)
Background The fully human monoclonal antibody bezlotoxumab binds Clostridioides (Clostridium) difficile toxin B and reduces recurrence rates in patients with C. difficile infection (CDI) receiving antibacterial treatment for a primary or recurrent e
Autor:
Adedayo Adedoyin, Dalya Guris, Vicente Boix, Uschi Stoutenburgh, Laurent Chesnel, Yoshihiko Murata, Richard N. Fedorak, Kajal B. Larson, Kathleen M. Mullane, Mandy Jin, Yves Pesant
Publikováno v:
Open Forum Infectious Diseases
Background Although the incidence of Clostridium difficile infection (CDI) is increasing, available CDI treatment options are limited in terms of sustained response after treatment. This phase 3 trial assessed the efficacy and safety of surotomycin,